American Well Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AMWL research report →
Range $11 – $16
Price Chart
About the company
American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Amwell Platform, a cloud-based enablement platform, digitally enables a scalable healthcare experience across all care settings; Amwell Carepoint, a device enable healthcare providers to leverage proprietary carts and transform existing tablets and TVs into digital access points in clinical settings; Amwell Converge, a platform and wraparound services of digital care into the in-person, automated, and virtual care settings; and Behavioral Health, a platform that offer students and faculty the right level of care. It also provides specialty care programs, including dermatology, musculoskeletal care, second opinion, and cardiometabolic care for patients and members; Amwell Medical Group network services consisting of primary and urgent care, behavioral health therapy, lactation counseling, and nutrition services.
- CEO
- Ido Schoenberg
- IPO
- 2020
- Employees
- 562
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on AMWL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $167.41M
- P/E
- -3.13
- PEG
- -0.04
- P/S
- 0.79
- P/B
- 0.87
- EV/EBITDA
- 0.39
- Div Yield
- 0.00%
- Gross Margin
- 45.96%
- Op Margin
- -27.85%
- Net Margin
- -27.03%
- ROE
- -25.49%
- ROIC
- -25.66%
Latest fiscal year · YoY change
- Revenue
- $249.32M-2.0%
- Gross Profit
- $132.86M+34.3%
- Op Income
- $-105,274,000
- Net Income
- $-95,700,000+54.0%
- EPS
- $-5.96+57.1%
- OCF Growth
- +48.2%
- FCF Growth
- +53.7%
- 52W High
- $15.16
- 52W Low
- $3.79
- 50D MA
- $12.75
- 200D MA
- $9.47
- Beta
- 1.69
- RSI (14)
- 35
- Avg Volume
- 112.11K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Amwell beat Q3 guidance on revenue and adjusted EBITDA, raised full-year outlook, and said it remains on track to reach positive operating cash flow and adjusted EBITDA in Q4.· November 3, 2026
- Q3 revenue was $49 million, down 12.9% year over year, but above the high end of guidance by $1 million.
- Adjusted EBITDA loss improved to $3.6 million from a $12.7 million loss a year ago; gross margin was 53%, up from 52.4%.
- Subscription revenue remained pressured at $23.9 million, down 22.5% year over year, while AMG visit revenue rose 11.7% to $23.7 million.
- Management raised full-year 2026 revenue guidance to $204 million-$206 million and reduced the full-year adjusted EBITDA loss outlook to $6.9 million-$7.9 million.
- The VA letter of intent and expected DHA contract renewal could add meaningful government business, but timing is still uncertain.
Total revenue in Q3 was $49 million, down approximately 12.9% year over year and $1 million above the high end of guidance. Subscription revenue was $23.9 million, down approximately 22.5% year over year and 6.8% sequentially. Amwell Medical Group visit revenue was $23.7 million, up approximately 11.7% year over year; AMG paid visits were about 301,000, essentially flat year over year, with revenue per visit of about $79, up about $8, or 11%. Gross profit was $26 million and gross margin was 53%, up about 57 basis points from 52.4% a year ago. Adjusted EBITDA was a loss of $3.6 million versus a loss of $12.7 million in Q3 2025; operating loss was $11.7 million versus $29.3 million a year ago. Cash and investments were about $181 million with zero debt at quarter-end. For Q4 2026, management guided to revenue of $48 million-$50 million and adjusted EBITDA of breakeven to a positive $1 million. For full-year 2026, revenue guidance was raised to $204 million-$206 million from $195 million-$205 million, and adjusted EBITDA loss guidance was tightened to $6.9 million-$7.9 million from $12 million-$16 million. Management also said full-year AMG visits should land at the high end of the previously communicated range of 1.32 million to 1.37 million.
Ido Schoenberg framed the quarter as another step in a multi-quarter turnaround, emphasizing that Amwell beat both revenue and adjusted EBITDA guidance and has now delivered on commitments for nine straight quarters. His message centered on a single-platform strategy: reduce vendor sprawl, improve member activation and outcomes, and serve payers and government clients with one branded integration and measurable results. He was notably constructive on the VA letter of intent and the DHA relationship, but careful to say the VA LOI is not yet a binding contract and timing remains uncertain.
Mark Hirschhorn highlighted that the quarter’s outperformance came mainly from stronger visit volumes and continued cost discipline. He gave the key figures: revenue of $49 million, gross margin of 53%, adjusted EBITDA loss of $3.6 million, and cash/investments of about $181 million with zero debt. He also said the company expects to end the year in a very similar cash position and guided Q4 to $48 million-$50 million of revenue and breakeven to positive $1 million adjusted EBITDA, while raising full-year revenue and improving the EBITDA loss outlook materially.
Analysts focused heavily on the VA LOI, the status of the DHA contract, and whether these federal opportunities change 2027 revenue or expense plans. Management said the VA process is in detailed negotiations, that implementation would likely begin after a future agreement is reached, and that timing is not yet known; for DHA, they said the current service is operating well and they expect to convert it into a longer-term direct agreement, but haven’t finalized terms. On growth, management said 2027 upside depends in part on the timing of those contracts, that the company is still in its best pipeline position ever, and that churn should be far less severe going forward, though some natural churn may remain.
The call showed improving profitability alongside a raised full-year outlook, suggesting the company is executing on its near-term financial targets. Management also sounded confident that the platform strategy, higher engagement, and government opportunities like the VA and DHA could support multi-year growth, while cost discipline keeps headcount and spending relatively contained.
Revenue is still declining year over year, and subscription revenue remains under pressure from previously disclosed churn. The biggest incremental opportunities from the VA and DHA are not yet contractually locked in, and management repeatedly said the timing and ramp are uncertain. Growth in 2027 may also be incomplete because some new opportunities have slipped later into the year rather than starting on January 1.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 89.6%
- Shares Outstanding
- 15.57M
- Float Shares
- 13.96M
of shares held by institutions
60 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Senvest Management, LLC | 1.33M | 0 |
| Morgan Stanley | 1.27M | ▼ 4.44K |
| Cable Car Capital, LP | 1.05M | ▲ 45.20K |
| Vanguard Capital Management LLC | 613.01K | ▲ 1.75K |
| Vanguard Group Inc | 612.61K | ▼ 37.49K |
| Acadian Asset Management LLC | 532.79K | ▲ 38.35K |
| Renaissance Technologies LLC | 397.32K | ▲ 134.10K |
| Marshall Wace, Llp | 355.66K | ▲ 247.60K |
| Blackrock, Inc. | 313.18K | ▼ 114.40K |
| Millennium Management LLC | 226.81K | ▲ 226.81K |
| Russell Investments Group, Ltd. | 174.74K | ▼ 7.50K |
| Two Sigma Investments, LP | 163.35K | ▲ 18.25K |
Held by 44 ETFs
Biggest fund positions in AMWL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | Gotlib Phyllis | sell | 6,677 |
| Oct 1, 26 | HIRSCHHORN MARK | sell | 4,282 |
| Oct 1, 26 | Zamansky Dmitry | sell | 8,442 |
| Oct 1, 26 | McNeice Paul Francis | sell | 653 |
| Sep 1, 26 | HIRSCHHORN MARK | sell | 10,751 |
| Sep 1, 26 | Gotlib Phyllis | sell | 3,573 |
| Sep 1, 26 | McNeice Paul Francis | sell | 112 |
| Jul 1, 26 | McNeice Paul Francis | sell | 653 |
| Jul 1, 26 | HIRSCHHORN MARK | sell | 4,299 |
| Jul 1, 26 | Zamansky Dmitry | sell | 8,460 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AMWL coverage
Recent articles, reports, and earnings notes.
Want a deeper read on AMWL?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
A $400 Billion Healthcare Opportunity: Telehealth Companies Positioned to Capitalize on a Massive Industry Shift
globenewswire.com · Nov 11
American Well (AMWL) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
zacks.com · Nov 10
American Well (AMWL) Shows Fast-paced Momentum But Is Still a Bargain Stock
zacks.com · Nov 10
Amwell Will Support New Federally Funded Research to Improve Engagement and Outcomes in Mental Health Care for Veterans and Service Members
globenewswire.com · Nov 10
Amwell makes grant to new employees under inducement plan
globenewswire.com · Nov 6
What American Well (AMWL) Said on Its Q3 Earnings Call
marketbeat.com · Nov 3
American Well Corporation (AMWL) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 3
American Well Corporation (AMWL) Reports Q3 Loss, Tops Revenue Estimates
zacks.com · Nov 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
